In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The association between renin-angiotensin-aldosterone system inhibitors dose reduction and risk of mortality and major adverse cardiovascular events in heart failure patients

Session Poster Session 2

Speaker Daniel Ayoubkhani

Congress : ESC Congress 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P1810

Authors : L Qin (Gaithersburg,US), P Mcewan (Cardiff,GB), D Ayoubkhani (Cardiff,GB), L Reeve (Cardiff,GB), S Grandy (Gaithersburg,US), E Palaka (Cambridge,GB), M Evans (Cardiff,GB)

Authors:
L. Qin1 , P. McEwan2 , D. Ayoubkhani2 , L. Reeve2 , S. Grandy1 , E. Palaka3 , M. Evans4 , 1AstraZeneca, Global Health Economics - Gaithersburg - United States of America , 2Health Economics and Outcomes Research Ltd - Cardiff - United Kingdom , 3AstraZeneca, Global Health Economics - Cambridge - United Kingdom , 4University Hospital Llandough, Diabetes Resource Centre - Cardiff - United Kingdom ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 378-379

Background: Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to have cardio-renal protective benefits for chronic heart failure (HF) patients. Previous studies have characterised patterns in adverse clinical outcomes associated with sub-optimal RAASi dosing, such as mortality and hospitalisation.

Purpose: To characterise the relationship between RAASi dosing and mortality and major adverse cardiovascular event (MACE) risk in HF patients.

Methods: Primary care data from the UK Clinical Practice Research Datalink (CPRD) were used to identify patients with a HF diagnosis from Jan 2006 to Dec 2015. Patients with a history of HF or chronic kidney disease stage 3+ prior to this period were excluded. RAASi therapies included angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs). Patient-time spent on RAASi therapies was divided into 90-day intervals and mean dose in each interval was calculated across RAASi therapies, expressed as a percentage of the total European Society of Cardiology (ESC) guideline-recommended maintenance dose. Clinical outcomes of interest included all-cause mortality and MACE, a composite of arrhythmia, heart failure, myocardial infarction, and stroke. Generalized Estimating Equations were used to estimate adjusted odds ratios (ORs) relating RAASi dosage to mortality and MACE, respectively, whilst controlling for confounders, including patient demographics, clinical measurements (e.g. estimated glomerular filtration rate), and concomitant medications.

Results: Data were available for 13,113 patients with mean age of 72.5 years (SD =13.10), of whom 59.6% were male, 16.2% had diabetes, 11.8% with history of myocardial infarction, and 6.6% with history of stroke. Over the study follow-up period (mean 5.1 years), 9,293 (70.9%), 2,344 (17.9%) and 4,179 (31.9%) patients were in receipt of ACEi, ARBs and/or MRAs, respectively. A total of 2,807 deaths and 14,402 MACE events were recorded giving a crude mortality rate of 8.1 per 100 patient-years and a crude MACE rate of 41.4 per 100 patient-years. After adjusting for potential confounding factors, the OR was 4.70 (p<0.0001) for mortality comparing patients on <50% with those on ≥50% of the ESC-recommended RAASi dose; the adjusted OR for MACE was 1.75 (p<0.0001) for patients prescribed <50% of the ESC-recommended RAASi dose compared to those prescribed ≥50%.

Conclusion: This real-world analysis of HF patients on ESC guideline-recommended RAASi therapies suggests associations between sub-optimal RAASi dose and increased risk of mortality and MACE. These results highlight the potentially negative impact of sub-optimal RAASi dosing, and the need for therapies that allow HF patients to be maintained on optimised guideline-recommended RAASi treatments.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are